A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade.
BACKGROUND
A common polymorphism of the beta(1)-adrenergic receptor Arg389Gly markedly affects function in vitro, but little is known about its in vivo significance.


RESULTS
Resting and exercise hemodynamic responses were measured in subjects homozygous for Arg389 (n = 21) or Gly389 (n = 13) alleles before and 3 hours after administration of a beta-blocker, atenolol. Demographic characteristics and atenolol concentrations were similar in the two genotypic groups. Genotype had a marked effect on resting hemodynamic responses to atenolol, with Arg389-homozygous subjects having a larger decrease in resting systolic blood pressure (8.7 +/- 1.3 mm Hg versus 0.2 +/- 1.7 mm Hg, P < .001) and mean arterial blood pressure (7.2 +/- 1.0 mm Hg versus 2.0 +/- 1.7 mm Hg, P = .009). Attenuation of exercise-induced hemodynamic responses by atenolol was not affected by genotype.


CONCLUSIONS
There is reduced sensitivity of Gly389 homozygotes to a beta-adrenergic receptor antagonist, and this polymorphism may be an important determinant of variability in response to beta-blockade.
Sofowora
G G
GG
Division of Clinival Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 373232-6602, USA.
Dishy
V
V
Muszkat
M
M
Xie
H G
HG
Kim
R B
RB
Harris
P A
PA
Prasad
H C
HC
Byrne
D W
DW
Nair
U B
UB
Wood
A J J
AJ
Stein
C M
CM
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000328:Adult; D000483:Alleles; D001262:Atenolol / Q000494:pharmacology*; D005260:Female; D005838:Genotype; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D008297:Male; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic; D011943:Receptors, Adrenergic, beta / Q000187:drug effects / Q000235:genetics
D000319:Adrenergic beta-Antagonists; D011943:Receptors, Adrenergic, beta; D001262:Atenolol